Sales ended at MNOK 133.8, 3.5% above first quarter last year (MNOK 129.3).
Currency neutral sales of own products was down 1%. Recurring sales remain high
at 75% or MNOK 83.5 (68% or MNOK 73.8) for the quarter. Strong quarter for the
direct sales operations in Europe and EMEA delivers 32% currency neutral growth
while growth in AMERICAS and APAC was influenced by strong comparables from Q1
last year. Operating profit (EBIT) for the quarter ended at MNOK 32.1 giving a
24.0% EBIT margin (MNOK 33.5, a 25.9% margin). Medistim's third-party
distribution business signed a contract with the cardiovascular company Peters
Surgical, to distribute their products in Sweden and Norway. Solid cash position
at quarter end with MNOK 170.3 and no long-term interest-bearing debt. The
General Assembly decided a dividend of NOK 4.50 (NOK 4.50) per share, a total of
MNOK 82.4.